Oncology Brothers: Practice-Changing Cancer Discussions
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Listen on:
Episodes
Thursday Jan 09, 2025
Thursday Jan 09, 2025
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul & Rohit Gosain are joined by Dr. Laura Huppert from UCSF to discuss key highlights from the San Antonio Breast Cancer Symposium 2024.
We dive into three crucial studies:1. INSEMA Study: Explore the findings on the potential omission of axillary surgery in early-stage hormone receptor-positive breast cancer and its implications for patient quality of life.2. KEYNOTE-522 Update: Learn about the latest insights on the use of Pembrolizumab in triple-negative breast cancer, including the search for predictive biomarkers and the impact of achieving pathological complete response (PCR).3. OlympiA Study Update: Discover the updated results on the use of Olaparib in BRCA-positive patients, highlighting its significant benefits in invasive disease-free survival and overall survival.
Join us as we unpack these important studies and their implications for clinical practice. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Tuesday Jan 07, 2025
Tuesday Jan 07, 2025
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Robert Orlowski from MD Anderson Cancer Center to discuss groundbreaking studies presented at ASH 2024 focused on multiple myeloma.
We dived into four key studies:1. AQUILA: Explore the impact of early intervention using daratumumab for smoldering myeloma, which showed improved progression-free survival (PFS) and overall survival (OS).2. Dara Based Quad Therapy: We discuss a meta-analysis reaffirming the use of quadruplet therapy with anti-CD38 for newly diagnosed multiple myeloma as the standard of care.3. CARTITUDE-4: study highlights the benefits of CAR-T therapy in earlier lines of treatment for patients with lenalidomide-refractory disease.4. Role of IVIG with BCMA Bispecific Antibodies: Discover how IVIG can reduce infection rates and improve overall survival when used alongside BCMA-targeted therapies.
Tune in for an insightful discussion that will enhance your understanding of the latest advancements in multiple myeloma treatment. Don't forget to check out our other episodes on CLL, myeloma, and lymphoma from ASH 2024!
Subscribe to the Oncology Brothers for more updates and expert insights in oncology!
Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
Thursday Jan 02, 2025
Thursday Jan 02, 2025
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of Zanidatamab, a bispecific HER2 antibody, for HER2 amplified, unresectable, locally advanced, or metastatic biliary tract cancer.Join us as we discuss the HERIZON-BTC-01 study with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center and one of the study's authors. We explore the significance of HER2 testing in biliary tract cancers, the study's design, key findings, and the implications for treatment strategies in the community oncology setting.
Key topics include:• Overview of biliary tract cancer and its treatment landscape• Study design and patient characteristics from the HERIZON-BTC-01 trial• Key findings, including overall response rates and duration of response• The importance of HER2 testing and its implications for treatment sequencing• Side effect profiles and management strategies for Zanidatamab• Future directions and ongoing clinical trials
Don't miss this insightful discussion that highlights the exciting advancements in HER2-targeted therapies for biliary tract cancer.Make sure to subscribe for more updates on recent FDA approvals, treatment algorithms, and conference highlights. We look forward to seeing you at GI ASCO 2025 in person!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Thursday Dec 26, 2024
Thursday Dec 26, 2024
Welcome to the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. John Allan from New York Presbyterian Hospital to discuss the latest highlights from ASH 2024, focusing on Chronic Lymphocytic Leukemia (CLL).
We dived into three key studies:1. SEQUOIA Update: Discover how this study led to the approval of Zanubrutinib in the frontline setting and its impressive progression-free survival rates compared to traditional chemotherapy.2. AMPLIFY Study: Learn about the exciting combination of Acalabrutinib with Venetoclax and Obinutuzumab, and how it may pave the way for the first oral doublet/triplet combination approval in the U.S.3. Ongoing Trials: We touch on the CELESTIAL TN-CLL trial and the promising combination of Zanubrutinib with Sonrotoclax, a new BCL-2 inhibitor.
Additionally, we discuss the evolving role of CAR-T therapy in CLL, especially for patients who have progressed through multiple lines of treatment.
Join us for an insightful discussion on the future of CLL treatment options, the importance of balancing efficacy and side effects, and the exciting developments in the field. Don't forget to check out our other ASH and SABCS 2024 discussions!
Subscribe to stay updated on the latest in oncology research and treatments!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Saturday Dec 21, 2024
Saturday Dec 21, 2024
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the rapidly evolving world of CAR T cell therapy, a groundbreaking treatment for various hematologic malignancies. Joined by experts Dr. Surbhi Sidana from Stanford University and Dr. Jason Westin from MD Anderson Cancer Center, we explore the mechanism of action of CAR T cells, their side effects, and management strategies.
Episode Highlights:
Understanding CAR T cell therapy and its application in hematologic malignancies and solid tumors.
Mechanism of action: How CAR T cells are engineered to target cancer cells.
Acute side effects: Cytokine release syndrome (CRS) and neurotoxicity, including clinical pearls for management.
Chronic side effects: Monitoring for infections, cytopenias, and the risk of secondary malignancies.
The importance of bridging therapy and managing tumor burden before CAR T treatment.
Insights for community oncologists on patient management and communication with CAR T centers.
Join us for an informative discussion that emphasizes the importance of recognizing and managing the unique side effects of CAR T therapy to ensure the best outcomes for patients. Don't forget to check out our other episodes for more insights into recent advances in hematology and oncology!
Subscribe for more discussions on FDA approvals, treatment algorithms, and conference highlights. We are the Oncology Brothers!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Thursday Dec 19, 2024
Thursday Dec 19, 2024
Welcome back to the Oncology Brothers podcast! In this episode, we dive into the highlights from ASH 2024, focusing on key studies in leukemia. Join hosts Drs. Rahul and Rohit Gosain as they discuss groundbreaking research with Dr. Uma Borate from The Ohio State University.
Episode Highlights:• KOMET 007 Study: An in-depth look at the Phase 1 study on the Menin inhibitor Ziftomenib, exploring its promising results in frontline settings for patients with NPM1 mutations and KMT2A rearrangements.• CPX351 vs. 7+3 Induction: A discussion on the liposomal formulation CPX351 and its effectiveness compared to the traditional 7+3 induction therapy, particularly in patients with myelodysplasia-related AML.• Venetoclax Combinations: Insights into the use of Venetoclax in combination with various therapies, including its role in treating patients without actionable mutations.
Key Takeaways:• The importance of NGS testing in identifying targetable mutations in AML.• Promising response rates and manageable toxicities associated with Menin inhibitors.• The ongoing debate regarding the best induction therapy for AML patients.
Don't miss this informative discussion that sheds light on the evolving landscape of leukemia treatment!
Subscribe for more updates on oncology topics, including lymphoma, CLL, and myeloma discussions from ASH 2024. Thanks for tuning in! We are the Oncology Brothers.
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Friday Dec 13, 2024
Friday Dec 13, 2024
In the second episode of a 4-part podcast series on HCC, the Oncology Brothers, Drs Rahul and Rohit Gosain, host a podcast discussion between Dr Lorenza Rimassa and Prof. Arndt Vogel on 2nd line treatment selection in advanced HCC and when to switch.
The discussion covers a range of topics, including 2nd line options for advanced HCC after progression on 1st line TKIs and IO-based therapies, as well as:
How to approach sequencing in clinical practice
The available data supporting sequencing strategies
When to switch to 2nd line therapy and what to consider when doing so
This is the second video podcast episode in a 4-part series. Access the rest of the series here:
Part 1 - The use of IO in unresectable HCC
Part 3 - Intermediate HCC: treatment options and strategies (coming soon)
Part 4 - The evolving role of IO in intermediate HCC (coming soon)
Clinical takeaways
Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions
When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life.
Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered
Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management
Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation.
Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Monday Dec 02, 2024
Monday Dec 02, 2024
Welcome to another episode of the Oncology Brothers! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the complexities of managing side effects associated with antibody drug conjugates (ADCs). Joined by expert guests Dr. Tian Zhang, a GU medical oncologist from UT Southwestern, and Dr. Erika Hamilton from Sarah Cannon Research Institute, the discussion focuses on three key ADCs: Enfortumab vedotin, Sacituzumab govitecan, and Trastuzumab deruxtecan (TDXD).
Episode Highlights:• Enfortumab vedotin: Learn about the common side effects such as skin toxicities, hyperglycemia, and neuropathy, and how to manage them effectively in clinical practice.• Sacituzumab govitecan: Explore the challenges of neutropenia, diarrhea, and fatigue, and the importance of individualized patient care.• Trastuzumab deruxtecan (TDXD): Understand the critical side effects including nausea, fatigue, and interstitial lung disease (ILD), and the strategies for prevention and management.
This episode emphasizes the importance of recognizing and acting on side effects that can significantly impact patient outcomes. Whether you're a healthcare professional or someone interested in oncology, this discussion will provide valuable insights into toxicity management for ADCs.
Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Thursday Nov 28, 2024
Thursday Nov 28, 2024
Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based combinations, along with emerging therapies and the latest clinical data. Topics also include: • Efficacy and safety of IO and IO combinations in HCC• How to select between the two 1st-line IO-based treatment options based on clinical factors• Future treatment in unresectable HCC Clinical Takeaways• Two 1st-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape• Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies• Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen (single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up• IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary• In clinical practice, treatment choice should be individualised, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Monday Nov 25, 2024
Monday Nov 25, 2024
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the recent FDA approval of Inavolisib for metastatic hormone receptor-positive breast cancer, based on the groundbreaking INAVO120 study.
Join us as we chat with Dr. Komal Jhaveri, a medical oncologist and senior author of the study from Memorial Sloan Kettering Cancer Center. We explored the study design, key findings, and the implications of this new treatment option for patients with PIK3CA mutations.
Key topics discussed include:• Overview of the INAVO120 study and its significance• The unique patient population targeted in the study• Key findings, including the impressive improvement in progression-free survival (PFS)• Side effects and management strategies for patients• The importance of genetic testing in treatment decisions
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment.
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!#OncologyBrothers #BreastCancer #ENAVOLacib #PIK3CA #CancerResearch #MedicalPodcast #Oncology
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com